Re: Neoadjuvant Sacituzumab Govitecan plus Pembrolizumab, Followed by Adjuvant Pembrolizumab, in Patients with Muscle-invasive Bladder Cancer (SURE-02): A Single-arm, Phase 2 Study
Elsevier ·
Аннотация у издателя не опубликована — полный текст доступен по ссылке ниже.
Re: Neoadjuvant Sacituzumab Govitecan plus Pembrolizumab, Followed by Adjuvant Pembrolizumab, in Patients with Muscle-invasive Bladder Cancer (SURE-02): A Single-arm, Phase 2 Study. // European Urology. – URL: https://www.sciencedirect.com/science/article/pii/S030228382602186X?dgcid=rss_sd_all
Re: Neoadjuvant Sacituzumab Govitecan plus Pembrolizumab, Followed by Adjuvant Pembrolizumab, in Patients with Muscle-invasive Bladder Cancer (SURE-02): A Single-arm, Phase 2 Study. European Urology. https://www.sciencedirect.com/science/article/pii/S030228382602186X?dgcid=rss_sd_all
“Re: Neoadjuvant Sacituzumab Govitecan plus Pembrolizumab, Followed by Adjuvant Pembrolizumab, in Patients with Muscle-invasive Bladder Cancer (SURE-02): A Single-arm, Phase 2 Study.” European Urology.
@article{article45309,
title = {Re: Neoadjuvant Sacituzumab Govitecan plus Pembrolizumab, Followed by Adjuvant Pembrolizumab, in Patients with Muscle-invasive Bladder Cancer (SURE-02): A Single-arm, Phase 2 Study},
journal = {European Urology},
url = {https://www.sciencedirect.com/science/article/pii/S030228382602186X?dgcid=rss_sd_all}
}